Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков
Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков
Бадалян О.Л., Савенков А.А. Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2018; 1: 10–15. DOI: 10.26442/2414-357X_2018.1.10-15
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Ламотриджин (Сейзар) – противоэпилептический препарат широкого спектра действия – более четверти века с успехом применяется в педиатрической эпилептологии. В статье описаны его свойства, а также влияние на когнитивные функции и возможности применения у детей и подростков с эпилепсией и синдромом дефицита внимания и гиперактивности.
Ключевые слова: ламотриджин, Сейзар, эпилепсия, синдром дефицита внимания и гиперактивности.
Key words: lamotrigine, Seizar, epilepsy, attention deficit disorder and of hyperactivity.
Ключевые слова: ламотриджин, Сейзар, эпилепсия, синдром дефицита внимания и гиперактивности.
________________________________________________
Key words: lamotrigine, Seizar, epilepsy, attention deficit disorder and of hyperactivity.
Полный текст
Список литературы
1. Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 6 (1): 51–6.
2. Besag FM et al. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282–6.
3. Bennett-Back O, Keren A, Zelnik N. Attention-deficit hyperactivity disorder in children with benign epilepsy and their siblings. Pediatr Neurol 2011; 44: 187–92.
4. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders 2002; 3: 217–25.
5. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (2): 160–3.
6. Ben-Menachem E, Scheepers B, Stodieck S. Epilepsy: fron consesus to daily practise. Acta Neurol Scand 2003; 108 (Suppl. 180): 5–15.
7. Dulac О. The use of Lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133–9.
8. Schlumberger E, Chavez F, Dulac O, Moszkowski J. Open study with lamotrigine (LTG) in child epilepsy. Seizure 1992; 1 (Suppl. 3): 9–21.
9. Frank LM, Casale E, Womble G, Manasco P. Lamictal is effective for the treatment of newly – diagnosed typical absence seizures in children and adolescents. Ann Neurol 1997; 42 (3): 489.
10. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–31.
11. Edwards KR, Sdckellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28–36.
12. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamictal in the treatment of epilepsy in children. Epilepsia 1996; 37 (Suppl. 3): 14.
13. Solowiej E, Sobaniec W, Kozik A, Ujma-Czapska B. The use of lamotrigine monotherapy in children with newly diagnosed partial epilepsy. Neurol Neurochir Pol 2000; 33 (Suppl. 1): 129–41.
14. Coppola G, Licciardi F, Sciscio N et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004; 26 (1): 26–9.
15. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamotrigine in the treatment of cryptogenic generalized epilepsy. Epilepsia 1997; 38 (Suppl. 3.): 66.
16. Betts Т, Goodwin G, Withers RM, Yuen AWC. Human safety of Lamotrigine. Epilepsia 1991; 32 (Suppl. 2): 17–21.
17. Genton P, Baue J, Duncan S et al. On the association Between Valproat and Polycystic Ovary Syndrome. Epilepsia 2001; 42 (3): 295–304.
18. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurology 2000; 57 (7): 1064–8.
19. Sabers A, Dam M, Rogvi A et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9–13.
20. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5.
21. Петрухин А.С., Бурд Г.С., Мухин К.Ю. и др. Ламиктал в лечении эпилепсии у детей. Соц. и клин. психиатрия. 1996; 6 (3): 121–4. / Petrukhin A.S., Burd G.S., Mukhin K.Iu. i dr. Lamiktal v lechenii epilepsii u detei. Sots. i klin. psikhiatriia. 1996; 6 (3): 121–4. [in Russian]
22. Gucuyener K et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109–12.
2. Besag FM et al. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282–6.
3. Bennett-Back O, Keren A, Zelnik N. Attention-deficit hyperactivity disorder in children with benign epilepsy and their siblings. Pediatr Neurol 2011; 44: 187–92.
4. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders 2002; 3: 217–25.
5. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (2): 160–3.
6. Ben-Menachem E, Scheepers B, Stodieck S. Epilepsy: fron consesus to daily practise. Acta Neurol Scand 2003; 108 (Suppl. 180): 5–15.
7. Dulac О. The use of Lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133–9.
8. Schlumberger E, Chavez F, Dulac O, Moszkowski J. Open study with lamotrigine (LTG) in child epilepsy. Seizure 1992; 1 (Suppl. 3): 9–21.
9. Frank LM, Casale E, Womble G, Manasco P. Lamictal is effective for the treatment of newly – diagnosed typical absence seizures in children and adolescents. Ann Neurol 1997; 42 (3): 489.
10. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–31.
11. Edwards KR, Sdckellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28–36.
12. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamictal in the treatment of epilepsy in children. Epilepsia 1996; 37 (Suppl. 3): 14.
13. Solowiej E, Sobaniec W, Kozik A, Ujma-Czapska B. The use of lamotrigine monotherapy in children with newly diagnosed partial epilepsy. Neurol Neurochir Pol 2000; 33 (Suppl. 1): 129–41.
14. Coppola G, Licciardi F, Sciscio N et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004; 26 (1): 26–9.
15. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamotrigine in the treatment of cryptogenic generalized epilepsy. Epilepsia 1997; 38 (Suppl. 3.): 66.
16. Betts Т, Goodwin G, Withers RM, Yuen AWC. Human safety of Lamotrigine. Epilepsia 1991; 32 (Suppl. 2): 17–21.
17. Genton P, Baue J, Duncan S et al. On the association Between Valproat and Polycystic Ovary Syndrome. Epilepsia 2001; 42 (3): 295–304.
18. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurology 2000; 57 (7): 1064–8.
19. Sabers A, Dam M, Rogvi A et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9–13.
20. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5.
21. Petrukhin A.S., Burd G.S., Mukhin K.Iu. i dr. Lamiktal v lechenii epilepsii u detei. Sots. i klin. psikhiatriia. 1996; 6 (3): 121–4. [in Russian]
22. Gucuyener K et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109–12.
2. Besag FM et al. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282–6.
3. Bennett-Back O, Keren A, Zelnik N. Attention-deficit hyperactivity disorder in children with benign epilepsy and their siblings. Pediatr Neurol 2011; 44: 187–92.
4. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders 2002; 3: 217–25.
5. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (2): 160–3.
6. Ben-Menachem E, Scheepers B, Stodieck S. Epilepsy: fron consesus to daily practise. Acta Neurol Scand 2003; 108 (Suppl. 180): 5–15.
7. Dulac О. The use of Lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133–9.
8. Schlumberger E, Chavez F, Dulac O, Moszkowski J. Open study with lamotrigine (LTG) in child epilepsy. Seizure 1992; 1 (Suppl. 3): 9–21.
9. Frank LM, Casale E, Womble G, Manasco P. Lamictal is effective for the treatment of newly – diagnosed typical absence seizures in children and adolescents. Ann Neurol 1997; 42 (3): 489.
10. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–31.
11. Edwards KR, Sdckellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28–36.
12. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamictal in the treatment of epilepsy in children. Epilepsia 1996; 37 (Suppl. 3): 14.
13. Solowiej E, Sobaniec W, Kozik A, Ujma-Czapska B. The use of lamotrigine monotherapy in children with newly diagnosed partial epilepsy. Neurol Neurochir Pol 2000; 33 (Suppl. 1): 129–41.
14. Coppola G, Licciardi F, Sciscio N et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004; 26 (1): 26–9.
15. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamotrigine in the treatment of cryptogenic generalized epilepsy. Epilepsia 1997; 38 (Suppl. 3.): 66.
16. Betts Т, Goodwin G, Withers RM, Yuen AWC. Human safety of Lamotrigine. Epilepsia 1991; 32 (Suppl. 2): 17–21.
17. Genton P, Baue J, Duncan S et al. On the association Between Valproat and Polycystic Ovary Syndrome. Epilepsia 2001; 42 (3): 295–304.
18. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurology 2000; 57 (7): 1064–8.
19. Sabers A, Dam M, Rogvi A et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9–13.
20. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5.
21. Петрухин А.С., Бурд Г.С., Мухин К.Ю. и др. Ламиктал в лечении эпилепсии у детей. Соц. и клин. психиатрия. 1996; 6 (3): 121–4. / Petrukhin A.S., Burd G.S., Mukhin K.Iu. i dr. Lamiktal v lechenii epilepsii u detei. Sots. i klin. psikhiatriia. 1996; 6 (3): 121–4. [in Russian]
22. Gucuyener K et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109–12.
________________________________________________
2. Besag FM et al. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282–6.
3. Bennett-Back O, Keren A, Zelnik N. Attention-deficit hyperactivity disorder in children with benign epilepsy and their siblings. Pediatr Neurol 2011; 44: 187–92.
4. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders 2002; 3: 217–25.
5. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (2): 160–3.
6. Ben-Menachem E, Scheepers B, Stodieck S. Epilepsy: fron consesus to daily practise. Acta Neurol Scand 2003; 108 (Suppl. 180): 5–15.
7. Dulac О. The use of Lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133–9.
8. Schlumberger E, Chavez F, Dulac O, Moszkowski J. Open study with lamotrigine (LTG) in child epilepsy. Seizure 1992; 1 (Suppl. 3): 9–21.
9. Frank LM, Casale E, Womble G, Manasco P. Lamictal is effective for the treatment of newly – diagnosed typical absence seizures in children and adolescents. Ann Neurol 1997; 42 (3): 489.
10. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–31.
11. Edwards KR, Sdckellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28–36.
12. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamictal in the treatment of epilepsy in children. Epilepsia 1996; 37 (Suppl. 3): 14.
13. Solowiej E, Sobaniec W, Kozik A, Ujma-Czapska B. The use of lamotrigine monotherapy in children with newly diagnosed partial epilepsy. Neurol Neurochir Pol 2000; 33 (Suppl. 1): 129–41.
14. Coppola G, Licciardi F, Sciscio N et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004; 26 (1): 26–9.
15. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamotrigine in the treatment of cryptogenic generalized epilepsy. Epilepsia 1997; 38 (Suppl. 3.): 66.
16. Betts Т, Goodwin G, Withers RM, Yuen AWC. Human safety of Lamotrigine. Epilepsia 1991; 32 (Suppl. 2): 17–21.
17. Genton P, Baue J, Duncan S et al. On the association Between Valproat and Polycystic Ovary Syndrome. Epilepsia 2001; 42 (3): 295–304.
18. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurology 2000; 57 (7): 1064–8.
19. Sabers A, Dam M, Rogvi A et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9–13.
20. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5.
21. Petrukhin A.S., Burd G.S., Mukhin K.Iu. i dr. Lamiktal v lechenii epilepsii u detei. Sots. i klin. psikhiatriia. 1996; 6 (3): 121–4. [in Russian]
22. Gucuyener K et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109–12.
Авторы
О.Л.Бадалян, А.А.Савенков
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*epileptolog@mail.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*epileptolog@mail.ru
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*epileptolog@mail.ru
________________________________________________
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*epileptolog@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.